The headline reads as positive (83% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › GEHC
Ge Healthcare Technologies Inc. (GEHC) stock analysis
BUY 39% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Ge Healthcare Technologies Inc. (GEHC) BUY with 39% confidence at a price of $75.82. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$75.82
Technical picture
The 14-day RSI is 82, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is 2.5x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $89.59 and the swing low is $58.68; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 1.77, which looks reasonably priced for its growth.
The company reports a profit margin of 10.0% and revenue growth of +7.2%.
In its latest quarter it earned $1.34 per share, which beat the $1.20 analysts expected, with revenue +7.2% year over year.
Wall Street's average rating is 1.8 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $83.45.
The next earnings report is expected around Feb 3, 2027; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $75.82, a target of $82.20 (+8.4%) and a stop-loss at $71.44 (-5.8%).
That is a reward-to-risk ratio of about 1.5 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 19, 2026 whatever the price does.
Entry$75.82
Target$82.20
Stop-loss$71.44
Reassess byNov 19, 2026
Research notes
GEHC’s bull case is accelerating organic growth, margin expansion, recovering Patient Care Solutions, and a record $23.7 billion backlog, supporting raised 2026 adjusted EPS guidance of $4.95–$5.05. The bear case is that orders grew only 4%, book-to-bill fell to 1.03, backlog declined sequentially, and fourth-quarter organic-growth guidance of 3%–4% trails consensus, while regulatory and installation delays could defer revenue into 2027 and beyond. The major recent catalyst was the October 28 Q3 report: revenue rose 7.2% to $5.51 billion, adjusted EPS increased 25.1% to $1.34, and management raised its full-year outlook, driving shares roughly 7% higher.
The model's one-paragraph read
Leans BUY — composite score +0.39 (BUY). Technicals: RSI 82.3, MACD bullish, price above SMA50. Fundamentals: PEG 1.77, margin 10.0%, revenue growth 7.2%. Financial results: YoY revenue +7.2%, last EPS surprise +11.7%, next earnings 2027-02-03. Smart Money Concepts: ranging / no clear structure. FinGPT news read: positive. Internet research: GEHC’s **bull case** is accelerating organic growth, margin expansion, recovering Patient Care Solutions, and a record $23.7 billion backlog, supporting raised 2026 adjusted EPS guidance of $4.95–$5.05. The **bear case** is that orders grew only 4%, book-to-bill fell to 1.03, backlog declined sequentially, and fourth-quarter organic-growth guidance of 3%–4% trails consensus, while regulatory and installation delays could defer revenue into 2027 and beyond. The major recent catalyst was the October 28 Q3 report: revenue rose 7.2% to $5.51 billion, adjusted EPS increased 25.1% to $1.34, and management raised its full-year outlook, driving shares roughly 7% higher. Suggested levels: entry $75.82, target $82.2, stop-loss $71.44, exit by 2026-11-19 (21-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for GEHC
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | BUY | 39% | $75.82 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on GEHC
Oct 29, 2026 · GE HealthCare raises 2026 outlook after positive Q3
- Oct 29, 2026: GE HealthCare raises 2026 outlook after positive Q3 (Medical Device Network)
Frequently asked questions
Is GEHC a buy right now?
As of Oct 29, 2026, our automated model rates Ge Healthcare Technologies Inc. (GEHC) BUY with 39% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for GEHC?
The model's most recent plan targets $82.20 with a stop-loss at $71.44, from an entry near $75.82.
When does Ge Healthcare Technologies Inc. report earnings next?
The next earnings report is expected around Feb 3, 2027.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.